EvolveImmune Therapeutics

What EvolveImmune Therapeutics does

EvolveImmune Therapeutics is a clinical-stage immuno-oncology company developing first-in-class, multi-specific T cell engagers with integrated CD2 costimulation to overcome cancer-driven immunodeficiency. Founded in 2020 and headquartered in Branford, Connecticut, with expanded research operations in a 20,000+ square foot New Haven facility, the company operates an approximate 50-100 person R&D organization focused on advancing its proprietary EVOLVE platform. Its lead program, EVOLVE104, is a trispecific CD3×CD2×ULBP2/5/6 T cell engager that received FDA IND clearance in August 2025 and entered a first-in-human Phase 1 trial (NCT07217171) in December 2025 for patients with advanced urothelial and squamous cell carcinomas of the bladder, lung, esophagus, skin, tongue, and anogenital region. The broader pipeline includes EVOLVE105 (CD20-targeted for B-cell malignancies and autoimmune disease), EVOLVE106 (B7-H4 for triple-negative and ER-low breast cancer), EVOLVE205 (2:1 CD20 bispecific for B-cell malignancies), EVOLVE101 (B-cell and myeloid malignancies including AML), EVOLVE220 (castration-resistant prostate cancer), and two undisclosed programs (EVOLVE108, EVOLVE109) partnered with AbbVie.

The EVOLVE platform is a humanized trispecific antibody format combining affinity-tuned CD3 binding with selective CD2 costimulatory engagement to amplify and sustain tumor killing while mitigating cytokine release syndrome and T cell dysfunction. The architecture is modular to enable alternative tumor antigen targeting and is supported by a complementary CRISPR-Cas9 T cell exhaustion screening platform that identifies genes (including BATF, CD70, FAS) distinct from the PD-1/PD-L1 checkpoint pathway for engineering improved CAR-T cells. The company differentiates on the scientific rationale that CD2 is positioned at the immune synapse and mediates stronger costimulation than CD28 or 4-1BB, with loss of the CD2-CD58 pathway linked to immune evasion and tumor progression.

EvolveImmune generates revenue through strategic pharmaceutical collaborations rather than commercial product sales. Under its October 2024 deal with AbbVie, the company received $65 million in upfront fees and equity investment and is eligible for up to $1.4 billion in aggregate option fees and milestones, plus tiered royalties on net sales; an $18 million milestone payment for development candidate nomination was achieved in April 2026. The company has raised approximately $120 million cumulatively across equity rounds and collaboration proceeds, with backing from Pfizer Ventures, Bristol Myers Squibb, Takeda Ventures, Solasta Ventures, Yonjin Ventures, and Elm Street Ventures. Upon product approval, commercialization is expected to leverage traditional pharmaceutical channels through oncology specialty pharmacies, hospital pharmacies, and treatment centers, supplemented by AbbVie's global oncology infrastructure for partnered programs.

Name

EvolveImmune Therapeutics

Legal name

EvolveImmune Therapeutics, Inc.

Website

https://evolveimmune.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

EvolveImmune Therapeutics is a clinical-stage immuno-oncology company developing trispecific T cell engagers with integrated CD2 costimulation to treat solid tumors and hematologic malignancies. Its lead program EVOLVE104 entered Phase 1 in December 2025 for advanced urothelial and squamous cell carcinomas.

Ownership category

akta.pro rank

Product category

Immuno-oncology Biologics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Immuno-oncology therapeutics
• Trispecific T cell engagers
• Cancer immunotherapy pipeline
• Clinical-stage biopharmaceuticals
• Biologics drug development

Headquarters

HQ city

Branford

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Collaboration and Licensing Revenue: EvolveImmune generates revenue through strategic partnerships with pharmaceutical companies. Under the AbbVie collaboration announced October 2024, the company received $65 million in upfront fees and equity investment, and is eligible for up to $1.4 billion in aggregate option fees and milestones, plus tiered royalty payments on net sales. Milestone payments (such as the $18M received in April 2026) represent additional revenue streams.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

EvolveImmune Therapeutics is a clinical-stage immuno-oncology company that develops first-in-class, multi-specific T cell engager biotherapeutics derived from its proprietary EVOLVE platform, which integrates CD2 costimulation along with CD3 engagement and tumor antigen binding to optimize T cell activation and overcome cancer-driven immunosuppression. The company is advancing a pipeline of wholly owned and partnered programs, including lead candidate EVOLVE104 (Phase 1 for solid tumors), CD20-targeted programs (EVOLVE105, EVOLVE205), a B7-H4 program (EVOLVE106), and undisclosed programs partnered with AbbVie.

Product overview

EvolveImmune Therapeutics is a clinical-stage immuno-oncology company developing first-in-class, multi-specific T cell engagers derived from its proprietary EVOLVE platform. The EVOLVE platform is a trispecific T cell engager technology with integrated CD2 costimulation designed to overcome cancer-driven immunodeficiency. The company has generated a pipeline of internal and partnered programs including: EVOLVE104 (lead program, Phase 1 for solid tumors targeting ULBP2/5/6), EVOLVE105 (CD20-targeted for B-cell malignancies), EVOLVE106 (B7-H4-targeted for breast cancer), EVOLVE205 (2:1 CD20 bispecific for B-cell malignancies), EVOLVE101 (novel antigen for B-cell and myeloid malignancies), EVOLVE220 (CRPC), and partnered programs EVOLVE108 and EVOLVE109 with AbbVie.

Differentiator

Problem solved

Functional benefit

Products and services

• EVOLVE Platform Proprietary humanized trispecific T cell engager platform with integrated CD2 costimulation, featuring affinity-tuned CD3 binding, selective CD2 costimulatory receptor binding, tumor antigen-dependent activation, and a modular design for alternative targeting. Licensed to AbbVie under an October 2024 collaboration and option-to-license agreement.
• EVOLVE104 First-in-class trispecific T cell engager (CD3×CD2×ULBP2/5/6) developed for solid tumors including urothelial carcinoma and squamous cell carcinomas of the lung, esophagus, skin, tongue, and anogenital region. In Phase 1 clinical trial (NCT07217171) as of December 2025.
• EVOLVE105 CD20-targeted CD2 co-stimulatory T cell engager engineered for treatment of B cell malignancies and B cell autoimmune disorders, with integrated CD2 costimulation designed to improve durability over standard CD20-targeted therapies.
• EVOLVE106 B7-H4-targeted T cell engager with integrated CD2 costimulation for treatment of advanced breast cancers, including ER-low and triple-negative breast cancer (TNBC).
• EVOLVE205 Highly potent 2:1 CD20-targeted CD2 co-stimulatory T cell engager designed for treatment of B cell malignancies and B cell autoimmune diseases, featuring a dual (2:1) bispecific format with enhanced tumor killing activity compared to benchmarks like glofitamab.
• EVOLVE108 Undisclosed target program partnered with AbbVie under the October 2024 collaboration and option-to-license agreement to develop multispecific biologics for oncology.
• EVOLVE109 Undisclosed target program partnered with AbbVie under the October 2024 collaboration and option-to-license agreement to develop multispecific biologics for oncology.
• EVOLVE220 Discovery-stage program targeting castration-resistant prostate cancer (CRPC) using the EVOLVE trispecific T cell engager architecture with integrated CD2 costimulation.
• EVOLVE101 First-in-class molecule targeting a novel tumor antigen for treatment of B cell malignancies and particular myeloid malignancies including acute myeloid leukemia, built on the EVOLVE trispecific T cell engager platform with integrated CD2 costimulation.

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• Memorial Sloan Kettering Cancer Center (MSK)coreStrategic or Co-development Partner · 8 April 2025Translational research collaboration to investigate expression of ULBP2 in muscle-invasive bladder cancer. Leverages MSK's world-leading capabilities in translational medicine with EvolveImmune's expertise in T cell engager immunobiology to accelerate development of treatment options for urothelial malignancies.
• AbbVieflagshipStrategic or Co-development Partner · 31 October 2024Collaboration and option-to-license agreement to develop multispecific biologics for multiple targets in oncology. AbbVie gains access to EvolveImmune's EVOLVE T cell engager platform. EvolveImmune received $65M upfront and is eligible for up to $1.4B in option fees and milestones plus tiered royalties on net sales.
• Kennedy Institute of Rheumatology (University of Oxford)coreTechnology or Integration · 14 June 2023Research partnership with Dr. Michael Dustin to evaluate molecular mechanism of action of EVOLVE platform using supported lipid bilayer (SLB) technology. Enables detailed assessment of EVOLVE's impact on immunological synapse behavior, molecular changes, and functional T cell responses.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Amgen: Amgen is the established leader in T cell engagers via its BiTE platform with approved products Blincyto (CD19×CD3) and Imdelltra (DLL3×CD3) for small cell lung cancer. Amgen represents the incumbent benchmark EvolveImmune must differentiate against in the T cell engager space.
• Roche: Roche/Genentech is a major player in bispecific antibodies with approved products Hemlibra, Columvi, Lunsumio, and an extensive pipeline of CD3-engaging bispecifics. Its resources and clinical experience make it the dominant large-cap competitor shaping T cell engager market dynamics.

Direct peers

• Xencor: Xencor is a clinical-stage biotech engineering XmAb bispecific antibody platforms including T cell engagers (e.g., plamotamab, tidutamab). Multiple Big Pharma partnerships (Astellas, Janssen, Novartis) make Xencor a directly comparable developer of engineered bispecific T cell engagers with proven partnership economics.
• Janux Therapeutics: Janux Therapeutics develops T cell engager (TCE) immunotherapies using a proprietary TRACTr platform that incorporates costimulatory signaling (e.g., CD28) to enhance T cell activation. As a clinical-stage biotech engineering next-generation T cell engagers with built-in costimulation, Janux is one of the most direct competitors to EvolveImmune's CD2-costimulatory EVOLVE platform.
• Harpoon Therapeutics: Harpoon Therapeutics developed T cell engagers (HPN328, HPN217) using its TriTAC platform targeting solid tumors and hematologic malignancies. Acquired by Merck in 2024 for ~$680M, Harpoon represents a recent comparable exit path for EvolveImmune-style T cell engager biotechs.
• MacroGenics: MacroGenics develops bispecific antibodies including T cell engagers (e.g., enoblituzumab, MGD024) using DART and TRIDENT platforms for oncology. Multiple pharma partnerships and pipeline breadth make it a directly comparable bispecific antibody platform developer.
• Cullinan Oncology: Cullinan Oncology develops oncology therapeutics including bispecific T cell engagers (CLN-978, CLN-418) for solid and hematologic cancers. Their clinical-stage pipeline and focus on engineered immune engagers makes them a directly comparable emerging biotech peer.
• Maverick Therapeutics: Maverick Therapeutics developed T cell engager platforms (COBRA) targeting solid tumors and was acquired by Eli Lilly. As a T cell engager platform biotech with strategic exit, it represents a comparable trajectory to where EvolveImmune could be positioned.

Peers

• Adagene:

Emerging players

• Triumvira Immunologics: Triumvira Immunologics develops TAC (T cell Antigen Coupler) platform, an alternative approach to T cell engagement for solid and hematologic tumors. As a clinical-stage biotech with novel T cell redirection technology, it represents an emerging adjacent peer with potentially overlapping target indications.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/evolveimmune-therapeutics
• Xx.com/evolveimmune

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EvolveImmune Therapeutics